Study Evaluating VBI-1901 Enrolling Recurrent GBM Patients in Second Dose Group
News
An Independent Data and Safety Monitoring Board (DSMB) unanimously recommended that the Phase 1/2 clinical trial evaluating VBI Vaccines’ VBI-1901 continue to enroll patients with recurrent glioblastoma (GBM) in a ... Read more